http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109942708-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 |
| filingDate | 2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109942708-B |
| titleOfInvention | anti-BCMA single domain antibody and application thereof |
| abstract | The present invention relates to an anti-BCMA single domain antibody comprising CDR1, CDR2, CDR3 and framework region sequences; wherein, the CDR1 sequence is shown in SEQ ID NO.1 or SEQ ID NO. 4; the CDR2 sequence is shown in SEQ ID NO.2 or SEQ ID NO. 5; the CDR3 sequence is shown in SEQ ID NO.3 or SEQ ID NO. 6. The invention also relates to the related application of the single domain antibody for resisting BCMA and a preparation method thereof. The anti-BCMA single domain antibodies B1 and B65 have excellent affinity with antigen, can only bind with BCMA, can not bind with other antigens (CD38, CD138 and the like), have good specificity on the BCMA, can effectively bind with BCMA positive target cells by the single domain antibodies B1 and B65, provide theoretical basis for the drugs for treating diseases or symptoms related to the expression of the BCMA, and are particularly suitable for treating multiple myeloma. |
| priorityDate | 2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 158.